Overview

Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment

Status:
Withdrawn
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This is a study of the chemistry of depression in people who are taking an antidepressant but it is not working well. The changes in brain chemicals that occur when an SSRI type antidepressant is supplemented with risperidone (Risperdal®) will be studied. Spinal fluid is used to measure chemical levels of dopamine, serotonin, and other chemicals thought to be involved in depression. The study has potential to help understand and treat depression.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborator:
Janssen, LP
Treatments:
Risperidone